Kiadis Pharma announces €12 million private placement with a U.S. healthcare investor
April 28, 2020 02:00 ET
|
Kiadis Pharma N.V.
THIS PRESS RELEASE AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND NOT FOR PUBLIC RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED...
Kiadis Pharma files first investigational new drug application with the U.S. FDA for natural killer (NK) cell therapy produced with PM21
April 09, 2020 02:30 ET
|
Kiadis Pharma N.V.
Kiadis Pharma files first...
Kiadis Pharma announces new data on ex-vivo FC21 expanded NK-cell therapy in 13 patients with relapsed/refractory acute myeloid leukemia will be presented at the European Society for Blood and Marrow Transplantation Annual Meeting*
March 10, 2020 03:30 ET
|
Kiadis Pharma N.V.
EBMT Abstract #A-1137-0005-00784 Amsterdam, The Netherlands, March 10, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage...
Kiadis Pharma to present at BioCapital Europe 2020
March 04, 2020 02:30 ET
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, March 4, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces...
Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R/R AML with off-the-shelf NK cells from universal donors
February 26, 2020 02:30 ET
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, February 26, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, and The Ohio State...
Kiadis Pharma announces change to management board
December 11, 2019 11:45 ET
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, December 11, 2019 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces...
Kiadis Pharma to present at the 2019 Piper Jaffray 31st Annual Healthcare Conference
November 25, 2019 13:21 ET
|
Kiadis Pharma N.V.
Kiadis Pharma to present at the 2019 Piper Jaffray 31st Annual Healthcare Conference Amsterdam, The Netherlands, November 25, 2019 – Kiadis Pharma...
Kiadis Pharma changes strategy to focus solely on development of Natural Killer (NK) Cell therapeutics and terminates development of ATIR101
November 12, 2019 12:00 ET
|
Kiadis Pharma N.V.
Kiadis will focus all future investments on developing off-the-shelf and haplo donor NK-cell therapies for the treatment of solid and liquid tumorsDiscontinues development of ATIR101, stopping...
Kiadis Pharma to present at the American Society of Hematology 2019 Annual Meeting
November 06, 2019 11:50 ET
|
Kiadis Pharma N.V.
ASH Abstract # ATIR101: 592, 4464; NK-cell Therapy (K-NK002) 1955 Phase II data analysis of ATIR101 as an adjunctive treatment following T-cell depleted haploidentical hematopoietic stem...
Kiadis Pharma to present at upcoming conferences in November 2019
November 05, 2019 11:50 ET
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, November 5, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces...